Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis

Update Il y a 2 ans
Reference: NCT00116454

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation.


Inclusion criteria

  • Carcinoma, hepatocellular ,Hepatitis, Viral, Human

Links